Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C62179
http://purl.obolibrary.org/obo/NCIT_C62179
|
|---|---|
| Preferred Name | Dacetuzumab |
| Definitions |
A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and inhibits the CD40 receptor, thereby inducing apoptosis and inhibiting cellular proliferation via antibody-dependent cellular cytotoxicity (ADCC) in cells that overexpress this receptor. The CD40 receptor, a member of the tumor necrosis factor (TNF) receptor super-family, is highly expressed on most B lineage hematologic malignancies including multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's disease and acute lymphoblastic leukemia. |
|---|---|
| prefLabel | Dacetuzumab
|
| label | Dacetuzumab
|
| PDQ_Closed_Trial_Search_ID | 365545
|
| code | C62179
|
| prefixIRI | NCIT:C62179
|
| in_subset |
See more
See less
|
| Display_Name | Dacetuzumab
|
| Preferred_Name | Dacetuzumab
|
| FDA_UNII_Code | UT59FF4T5X
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Dacetuzumab
|
| CAS_Registry | 880486-59-9
|
| NCI_Drug_Dictionary_ID | 365545
|
| Legacy Concept Name | SGN-40
|
| type | |
| ALT_DEFINITION | A monoclonal antibody that binds to cells that have the CD40 antigen on their surface, including cells from multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. SGN-40 is being studied in the treatment of cancer. It is a type of monoclonal antibody.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 365545
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C2742509
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |